SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

IMURAN TABLETS

Registration number

IMURAN 25 MG TABLETS * IMURAN 50 MG TABLETS * IMUREK FILMTABLETTEN * IMUREL **Synonyms**

TABLETS * AZATHIOPRINE, FORMULATED PRODUCT

06-November-2014 Issue date

Version number 13

Revision date 06-November-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Fmail Address: msds@gsk.com Website: www.qsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Caution - Pharmaceutical agent. See section 11 for additional information on health hazards. 2.3. Other hazards

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: IMURAN TABLETS SDS MALTA

CAS-No. / EC No. REACH Registration No. INDEX No. **Chemical name** % **Notes**

AZATHIOPRINE 31.4 - < 446-86-6

31,8 207-175-4

Classification: **DSD:** Carc. Cat. 1;R45, Muta. Cat. 1;R46, Muta. Cat. 2;R46, Repr. Cat. 2;R61,

Xn;R22-48, Xi;R36-37-38, R43

Acute Tox. 4;H302, Skin Irrit. 2;H315, Skin Sens. 1;H317, Eye Irrit. 2;H319,

STOT SE 3;H335, Muta. 1B;H340, Carc. 1A;H350, Repr. 1B;H360, STOT RE

Starch 10 - < 20 9005-25-8

232-679-6

Classification: DSD: -

CLP: -

HYDROXYPROPYL METHYL 1 - < 39004-65-3

CELLULOSE

Classification: DSD: -

CLP: -

MAGNESIUM STEARATE < 1 557-04-0

209-150-3

Classification: DSD: -

CLP: -

Titanium dioxide < 0.2 13463-67-7

236-675-5

Classification: DSD: -

CLP: -

Other components below reportable levels 40 - < 50

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

The full text for all R- and H-phrases is displayed in section 16. **Composition comments**

SECTION 4: First aid measures

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Skin contact

Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large Ingestion amount does occur, call a poison control centre immediately. Do not induce vomiting without

advice from poison control center.

4.2. Most important symptoms and effects, both acute and

delayed

Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), nausea, vomiting, increased susceptibility to infection.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

Material name: IMURAN TABLETS 123443 Version #: 13 Revision date: 06-November-2014 Issue date: 06-November-2014

SECTION 5: Firefighting measures

General fire hazards

No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

media

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

Move containers from fire area if you can do so without risk.

procedures Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or

6.2. Environmental precautions

6.3. Methods and material for

containment and cleaning up

6.4. Reference to other

confined areas. Following product recovery, flush area with water.

Avoid discharge into drains, water courses or onto the ground.

sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Observe good industrial hygiene practices.

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s)

Medicinal Product.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK Components	Туре	Value	Note
AZATHIOPRINE (CAS 446-86-6)	8 HR TWA	3 mcg/m3	
	OHC	4	Carcinogen
		4	Reproductive hazard
		4	SKIN SENSITISER
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)	OHC	1	
ological limit values	No biological exposure limits noted for the ingredient(s).		
commended monitoring ocedures	Follow standard monitoring procedures.		
rived no-effect level (DNEL)	Not available.		
edicted no effect	Not available.		

Material name: IMURAN TABLETS

concentrations (PNECs)

Exposure guidelines

8.2. Exposure controls

Appropriate engineering

controls

General ventilation normally adequate. An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the

outcome of a site- or operation-specific risk assessment.

Individual protection measures, such as personal protective equipment

Personal protection equipment should be chosen according to the CEN standards and in **General information**

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace.

Eye/face protection If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166). Not normally

needed.

Skin protection

- Hand protection For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical

resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time). Not

normally needed.

Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for - Other

splashes, EN ISO 13982 for dust). Not normally needed.

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators. No personal respiratory protective equipment normally required.

Wear appropriate thermal protective clothing, when necessary. Thermal hazards

Always observe good personal hygiene measures, such as washing after handling the material Hygiene measures

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance

from a qualified environment, health and safety professional.

Environmental exposure controls

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid. **Form** Tablet.

Colour Not available. Odour Not available. **Odour threshold** Not available. Not available. pН Not available. Melting point/freezing point Initial boiling point and boiling

range

Not available.

Flash point Not available. Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Not available. Vapour pressure Vapour density Not available. Relative density Not available.

Solubility(ies)

Not available. Solubility (water) Solubility (other) Not available. Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available. **Decomposition temperature** Not available.

Material name: IMURAN TABLETS 123443 Version #: 13 Revision date: 06-November-2014 Issue date: 06-November-2014 ViscosityNot available.Explosive propertiesNot available.Oxidizing propertiesNot available.

9.2. Other informationNo relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoidContact with incompatible materials.

10.5. Incompatible materials Strong oxidising agents.

10.6. Hazardous None known. Irritating and/or toxic fumes and gases may be emitted upon the product's

decomposition products decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Health injuries are not known or expected under normal use.

Eve contact Health injuries are not known or expected under normal use.

Ingestion Health injuries are not known or expected under normal use. May be harmful if swallowed.

Symptoms Accidental exposure or contact might produce: nausea, vomiting, symptoms of hypersensitivity

11.1. Information on toxicological effects

Acute toxicity Expected to be a low hazard for usual industrial or commercial handling by trained personnel. May

(such as skin rash, hives, itching, and difficulty breathing), increased susceptibility to infection.

be harmful if swallowed.

Components Species Test results

AZATHIOPRINE (CAS 446-86-6)

Acute

Oral

LD50 Rat 400 mg/kg

HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)

Acute

Oral

LD50 Rat > 2000 mg/kg

MAGNESIUM STEARATE (CAS 557-04-0)

Acute

Oral

LD50 Rat > 2000 mg/kg

Titanium dioxide (CAS 13463-67-7)

Acute

Inhalation

LC50 Rat 6820 mcg/m3

Oral

LD50 Rat > 24 g/kg

Chronic

Inhalation

LOEC Rat 8,6 mg/m3, 1 years TiO2 accumulated in

interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.

NOAEC Rat 250 mg/m3, 2 years Highest dose

5 mg/m3, 24 months

Material name: IMURAN TABLETS SDS MALTA

Test results Components **Species Subacute** Inhalation LOEL Rat 0,1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid. NOAEC Guinea pig 26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract. Oral NOAEL Rat 100000 ppm, 14 Day Dietary study, highest dose tested. **Subchronic**

* Estimates for product may be based on additional component data not shown.

Rat

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

Inhalation

TITANIUM DIOXIDE 0, Literature data

Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human

Acute dermal irritation; OECD 404, Literature data

3,2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of

pulmonary inflammation.

Result: Non-irritant Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE 0

Serious eye damage/eye

irritation

Health injuries are not known or expected under normal use.

TITANIUM DIOXIDE OECD 405, Literature data

Result: Mild irritant Species: Rabbit

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory sensitisationNo studies have been conducted. **Skin sensitisation**May cause an allergic skin reaction.

Maximisation assay (Magnusson and Kligman)

HYDROXYPROPYL METHYL CELLULOSE Result: negative

Species: Guinea pig

Sensitisation

AZATHIOPRINE

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: negative Species: Guinea pig

Test Duration: 48 hour exposure

Occupational exposure, Literature data

Result: Low incidence of contact hypersensitivity.

Species: Human

TITANIUM DIOXIDE Patch test, Literature data

Result: negative Species: Human

Germ cell mutagenicity May cause genetic defects.

Mutagenicity

AZATHIOPRINE Ames Assay, GLP assay; Literature data

Result: positive
Ames, Literature data
Result: negative

Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Material name: IMURAN TABLETS

TITANIUM DIOXIDE

SDS MALTA

123443 Version #: 13 Revision date: 06-November-2014 Issue date: 06-November-2014

Mutagenicity

TITANIUM DIOXIDE Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: positive

AZATHIOPRINE Micronucleus Test, GLP assay; Literature data

Result: positive

TITANIUM DIOXIDE Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: positive

Carcinogenicity

TITANIUM DIOXIDE

Contains a material (Azathioprine) classified as a carcinogen by external agencies.

0,5 mg/m3, Literature data

Result: negative Species: Rat

Test Duration: 24 months 0,72 - 14,8 mg/m3, Literature data

Result: negative Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months 25000 - 50000 ppm, Dietary study

Result: negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative Species: Rat

7,2 - 14,8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

Literature search Result: positive

AZATHIOPRINE

IARC Monographs. Overall Evaluation of Carcinogenicity

AZATHIOPRINE (CAS 446-86-6) 1 Carcinogenic to humans.

Titanium dioxide (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

Reproductive toxicity May damage fertility or the unborn child.

Reproductivity

AZATHIOPRINE Literature search

Result: Positive for teratogenicity, fertiltiy effects and may

affect the quality of breast milk.

Specific target organ toxicity -

single exposure

Not available.

Specific target organ toxicity -

repeated exposure

Causes damage to organs through prolonged or repeated exposure.

AZATHIOPRINE Literature search

Organ: Immune system, Bone marrow and formation of blood

cells, Liver, Kidney

Aspiration hazard Not likely, due to the form of the product.

Mixture versus substance

information

No information available.

Other information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Components Species Test results

AZATHIOPRINE (CAS 446-86-6)

Acute

IC50 Activated sludge > 1000 mg/l, 3 hours

Material name: IMURAN TABLETS SDS MALTA

Components **Species Test results** Aquatic Acute EC50 Green algae (Scenedesmus > 100 mg/l, 72 hours Static test Algae subspicatus) **NOEC** Green algae (Scenedesmus 100 mg/l, 72 hours Static test subspicatus) Crustacea EC50 Water flea (Daphnia magna) > 100 mg/l, 48 hours Static test **NOEC** Water flea (Daphnia magna) > 100 mg/l, 48 hours Static test HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3) Aquatic Acute Fish EC50 Fish > 100 mg/l, 96 hours MAGNESIUM STEARATE (CAS 557-04-0) Aquatic Acute Fish EC50 Orange-red killfish (Adult Oryzias 130 mg/l, 96 hours latipes)

Titanium dioxide (CAS 13463-67-7)

Aquatic

Acute

Crustacea EC50 Water flea (Daphnia magna) > 1000 mg/l, 48 hours Static test

12.2. Persistence and degradability

egradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

AZATHIOPRINE 4 %, 28 days Modified Zahn-Wellens, DOC removal.,

Activated sludge

4 %, 28 days Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge

MAGNESIUM STEARATE 77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-ready)

AZATHIOPRINE 11 %, 28 days Modified Sturm test.

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

AZATHIOPRINE -0,787 HYDROXYPROPYL METHYL CELLULOSE -5

Bioconcentration factor (BCF)

HYDROXYPROPYL METHYL CELLULOSE 3,2 Estimated
MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5,86 Estimated

Mobility in general

Volatility

Henry's law

AZATHIOPRINE 0 atm m³/mol, 25 C Estimated HYDROXYPROPYL METHYL CELLULOSE 0 atm m³/mol Estimated

Material name: IMURAN TABLETS

123443 Version #: 13 Revision date: 06-November-2014 Issue date: 06-November-2014

^{*} Estimates for product may be based on additional component data not shown.

12.5. Results of PBT

and vPvB assessment

Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste codeThe Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

Special precautionsDispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Material name: IMURAN TABLETS SDS MALTA

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations Young people under 18 years old are not allowed to work with this product according to the EU

Directive 94/33/EC on the protection of young people at work. Follow national regulation for work

with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

References GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

Revision information

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R22 Harmful if swallowed.

R36 Irritating to eyes.

R37 Irritating to respiratory system.

R38 Irritating to skin.

R43 May cause sensitization by skin contact.

R45 May cause cancer.

R46 May cause heritable genetic damage.

R48 Danger of serious damage to health by prolonged exposure.

R61 May cause harm to the unborn child.

H302 Harmful if swallowed. H315 Causes skin irritation.

H317 May cause an allergic skin reaction. H319 Causes serious eye irritation. H335 May cause respiratory irritation. H340 May cause genetic defects.

H350 May cause cancer.

H360 May damage fertility or the unborn child.

H372 Causes damage to organs through prolonged or repeated exposure. Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Ingredients

Exposure Controls / Personal Protection:

Physical & Chemical Properties: Ecological Information: Ecotoxicity

Transport Information: Agency Name and Packaging Type/Transport Mode Selection

Regulatory Information: Risk Phrases - Class.

GHS: Classification

Training information Follow training instructions when handling this material.

DisclaimerThe information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Material name: IMURAN TABLETS